194 related articles for article (PubMed ID: 2346318)
1. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
[TBL] [Abstract][Full Text] [Related]
2. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
3. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
4. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
5. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
9. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
Fram RJ; Woda BA; Wilson JM; Robichaud N
Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
[TBL] [Abstract][Full Text] [Related]
10. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.
Waud WR
Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
[TBL] [Abstract][Full Text] [Related]
12. Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II) or vincristine sulfate.
Osmak M
Neoplasma; 1992; 39(3):197-202. PubMed ID: 1528326
[TBL] [Abstract][Full Text] [Related]
13. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
15. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
16. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): cross-resistance patterns.
Beketić-Oresković L; Osmak M
Neoplasma; 1994; 41(3):171-6. PubMed ID: 7935986
[TBL] [Abstract][Full Text] [Related]
17. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
Frühauf S; Zeller WJ
Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) cytotoxicity by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
Swinnen LJ; Ellis NK; Erickson LC
Cancer Res; 1991 Apr; 51(8):1984-9. PubMed ID: 2009517
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.
Wallner KE; DeGregorio MW; Li GC
Cancer Res; 1986 Dec; 46(12 Pt 1):6242-5. PubMed ID: 3779644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]